



EAST LANCASHIRE HEALTH ECONOMY MEDICINES MANAGEMENT BOARD

MINUTES OF THE TEAMS MEETING 18th October 2023

PRESENT:

Dr L Rogan (LR)	Strategic Director of Medicines, Research and Clinical Effectiveness NHS EL ICB
Dr S Ramtoola (SR)	Consultant Physician, ELHT (Chairperson)
Mr J Vaughan (JV)	Senior Medicines Commissioning Pharmacist NHS EL/BwD ICB
Ms Ana Batista (AB)	Medicines Information Pharmacist ELHT
Mr U Akram (UA)	Deputy Lead Pharmacist, LS CFT
Ms L Prince (LP)	Senior Medicines Management Technician, EL ICB
Mrs H Robinson (HR)	Divisional Lead Pharmacist – MEC
Mr Steven Simpson	Chief Pharmacist ELHT (incoming)
Mr Neil Fletcher	Chief Pharmacist ELHT (outgoing)

2023/130: APOLOGIES:

Mr V Goodey (VG)	Assistant Director of Pharmacy, Clin Service ELHT
Dr F Shah (FS)	

2023/131: DECLARATION OF INTEREST:

SR declared interest for Lilly/Novo/AZ.

2023/132: MINUTES OF SEPTEMBER TEAM MEETING:

Accepted as an accurate record.

Action: September minutes to be uploaded to ELMMB website

2023/133: MATTERS ARISING:

NF introduced Steven Simpson, the new chief pharmacist for ELHT to the group.

2023/134: NEW PRODUCT REQUEST:

Intracinol®: Request from Dr P V David, Consultant Ophthalmic Surgeon. Intracinol® is a medical device licensed for ophthalmic use, containing triamcinolone acetonide 40mg/ml in a single use 1.1ml vial in suspension. It will be used by ophthalmology surgeons to opacify the vitreous and to facilitate surgical removal, including in patients with diabetic macular oedema, macular hole or chronic uveitis. Intracinol® will ensure patient safety as it is licensed for this use and is cost-effective.

This is intended to replace the current off-label use of Kenalog®. It was agreed that Intracinol® would be added to formulary as an interim approved product. LR requested that the product information be sent to LSCMMG for review and inclusion in the Lancashire-wide formulary

RED Traffic Light



Resolved: Intracinol® to be added to formulary

2023/135: Formulary Updates

None for October

2023/136: LSCMMG Consultations – November 2023 [deadline 2nd November 2023]

- a. **Ranolazine RAG rating review:** proposed RAG status is Green restricted. ELMMB currently has an AMBER RAG for Ranolazine as expressions were made that GPs would not be happy to initiate and prescribe in Primary Care. It was decided that a Green restricted RAG was agreeable.
- b. **Position Statement: requests from private prescribers to transfer or share prescribing with an NHS GP:**
To feedback that if a private provider is willing to sign up to our local shared care agreement and the patient remained under the private specialist and they provided the same element of specialist care and monitoring the patient would receive under the NHS, then the GP could consider prescribing.
- c. **Denosumab RAG change** – this has been circulated to the Cancer directorate for comment. ELMMB has 120mg denosumab on formulary as RED for skeletal-related events in adults with bone metastases from solid tumours. Changing to shared care has implications for primary care that need to be considered and fed back to LSCMMG.
- d. **Azithromycin RAG and prescriber information sheet consultation:** Shared for comment with the respiratory consultants. AB to feedback comments received.

2023/137 LSCMMG Recommendations – September 2023

- a. Gout Guideline: – updated guideline
- b. Erectile Dysfunction guideline: – updated [Added invicorp® and avanafil position updated]
- c. Melatonin Pathway (Children): – New guidance
- d. Lithium Shared care guideline: – updated/reviewed.
- e. COPD desktop guideline: [Treatment algorithms updated to reflect NICE NG115 (2018) and GOLD (2019)]

Resolved: items acknowledged by ELMMB. Website will be updated accordingly.

2023/138 NICE Guidance from September 2023

NG234: Spinal metastases and metastatic spinal cord compression. Published 6th September 2023

NG192: Caesarean birth. Updated 6th September 2023

NG50: Cirrhosis in over 16s: assessment and treatment. Updated 8th September 2023

NG148: Acute kidney injury: prevention, detection, and management. Updated 28th September 2023

NG235: Intrapartum care. Published 29th September 2023.

2023/139 NICE Recommendations: September 2023

Mavacamtem for treating symptomatic obstructive hypertrophic cardiomyopathy is recommended as an option by NICE TA913

NHS England Commissioned

RED Traffic Light



Pembrolizumab for previously treated endometrial, biliary, colorectal, gastric or small intestine cancer with high microsatellite instability or mismatch repair deficiency is recommended by NICE TA914.

NHS England Commissioned

RED Traffic Light

Resolved: ELMMB website will be updated accordingly

2023/140 NICE Highly Specialised Technologies: September 2023

HST28 Birch bark extract for treating epidermolysis bullosa. Published 20th September 2023

Resolved: Item acknowledged by ELMMB, website will be updated

2023/141 EAMS (Early access to medicines scheme): September 2023

None

Standing Items:

2023/142 For Action/Information: Lancashire & South Cumbria Medicines Management Group (LSCMMG)

LSCMMG-minutes Draft 14.09.2023

Resolved: Draft minutes acknowledged

2023/143 For Action/Information: Lancashire & South Cumbria FT Drugs and Therapeutics Committee

Occurs every two months.

Minutes not available.

2023/144 For Action/Information: Antimicrobial Stewardship Committee (ASC)

Minutes not available.

2023/145 Any Other Business

Shortage of ADHD medicines: LR informed the group of recent shortages and supply issues with all ADHD drugs. JV has linked in with UA for advice and guidance to be sent out to teams. Paediatric patients have been the main issue. A regional response has been agreed, but nothing nationally. Some products are slowly coming back into stock but are limited.

DATE OF NEXT MEETING – Wednesday 15th November 2023 12.30pm via 'Microsoft Teams'

PLEASE NOTE: The December meeting will be held on 21st December 2023



**ACTION SHEET FROM
EAST LANCASHIRE HEALTH ECONOMY
MEDICINES MANAGEMENT BOARD**

WEDNESDAY 18th October 2023

MINUTE NUMBER	DESCRIPTION	ACTION	DATE
2023/128	Use of Semaglutide in overweight/obese patients with NASH: update to pathway/commissioning situation to be provided as and when there is an update.	All	April 24